GT Biopharma, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 0.227 million compared to USD 5.44 million a year ago. Basic loss per share from continuing operations was USD 0.3 compared to USD 5.1 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.6 USD | -28.21% | +75.37% | -26.80% |
08:18pm | Top Midday Decliners | MT |
05:35pm | GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.80% | 10.77M | |
+37.78% | 705B | |
+32.82% | 583B | |
-3.51% | 364B | |
+19.94% | 332B | |
+5.14% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+9.32% | 169B |
- Stock Market
- Equities
- GTBP Stock
- News GT Biopharma, Inc.
- GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023